While CaMKII inhibitors are actively studied as a possible treatment strategy for patients with cardiomyopathy, it might be interesting to consider whether those inhibitors could benefit patients with neurodevelopmental disorders caused by CaMKII gain-of-function pathogenic variants. Here, CAMK2G is linked to cardiomyopathy.